{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:10:06Z","timestamp":1776485406019,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009795","name":"Pancreatic Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008167","name":"Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11307-017-1112-8","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T18:25:56Z","timestamp":1503685556000},"page":"292-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody"],"prefix":"10.1007","volume":"20","author":[{"given":"Julia Bagu\u00f1a","family":"Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Kersemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Koustoulidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kinchesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Smart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M (2010) Pancreatic cancer. New Engl J Med 362:1605\u20131617","journal-title":"New Engl J Med"},{"key":"1112_CR2","first-page":"99","volume":"9","author":"G Garcea","year":"2008","unstructured":"Garcea G, Dennison AR, Pattenden CJ et al (2008) Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. J Pancreas 9:99\u2013132","journal-title":"J Pancreas"},{"key":"1112_CR3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1091-255X(01)00058-0","volume":"6","author":"N Alazraki","year":"2002","unstructured":"Alazraki N (2002) Imaging of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastrointest Surg 6:136\u2013138","journal-title":"J Gastrointest Surg"},{"key":"1112_CR4","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.3748\/wjg.v20.i24.7864","volume":"20","author":"ES Lee","year":"2014","unstructured":"Lee ES, Lee JM (2014) Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol 20:7864\u20137877","journal-title":"World J Gastroenterol"},{"key":"1112_CR5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2013.42","volume":"10","author":"O Strobel","year":"2013","unstructured":"Strobel O, Buchler MW (2013) Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol 10:203\u2013205","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1112_CR6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1245\/s10434-011-1970-2","volume":"19","author":"K Tsutsumi","year":"2012","unstructured":"Tsutsumi K, Sato N, Tanabe R et al (2012) Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma. Ann Surg Oncol 19:491\u2013499","journal-title":"Ann Surg Oncol"},{"key":"1112_CR7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2353\/jmoldx.2008.070115","volume":"10","author":"G Feldmann","year":"2008","unstructured":"Feldmann G, Maitra A (2008) Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diag 10:111\u2013122","journal-title":"J Mol Diag"},{"key":"1112_CR8","doi-asserted-by":"crossref","first-page":"e1000046","DOI":"10.1371\/journal.pmed.1000046","volume":"6","author":"HC Harsha","year":"2009","unstructured":"Harsha HC, Kandasamy K, Ranganathan P et al (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6:e1000046","journal-title":"PLoS Med"},{"key":"1112_CR9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/17474124.2015.965145","volume":"9","author":"C Jenkinson","year":"2015","unstructured":"Jenkinson C, Earl J, Ghaneh P et al (2015) Biomarkers for early diagnosis of pancreatic cancer. Exp Rev Gastroenterol Hepatol 9:305\u2013315","journal-title":"Exp Rev Gastroenterol Hepatol"},{"key":"1112_CR10","first-page":"8614","volume":"63","author":"CA Iacobuzio-Donahue","year":"2003","unstructured":"Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al (2003) Highly expressed genes in pancreatic ductal adenocarcinomas. Cancer Res 63:8614\u20138622","journal-title":"Cancer Res"},{"key":"1112_CR11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1309\/K144PHVDDUPDD401","volume":"121","author":"LS Nichols","year":"2004","unstructured":"Nichols LS, Ashfaq R, Iacobuzio-Donahue CA (2004) Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 121:226\u2013230","journal-title":"Am J Clin Pathol"},{"key":"1112_CR12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/gutjnl-2012-302577","volume":"62","author":"A Neesse","year":"2013","unstructured":"Neesse A, Hahnenkamp A, Griesmann H et al (2013) Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut 62:1034\u20131043","journal-title":"Gut"},{"key":"1112_CR13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2967\/jnumed.114.152496","volume":"56","author":"M Mosley","year":"2015","unstructured":"Mosley M, Knight J, Neesse A et al (2015) Claudin-4 SPECT imaging allows detection of aplastic lesions in a mouse model of breast cancer. J Nucl Med 56:745\u2013751","journal-title":"J Nucl Med"},{"key":"1112_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s13277-012-0373-8","volume":"33","author":"G Kramer-Marek","year":"2012","unstructured":"Kramer-Marek G, Capala J (2012) The role of nuclear medicine in modern therapy of cancer. Tumour Biol 33:629\u2013640","journal-title":"Tumour Biol"},{"key":"1112_CR15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469\u2013483","journal-title":"Cancer Cell"},{"key":"1112_CR16","first-page":"1","volume":"2","author":"M Brom","year":"2012","unstructured":"Brom M, Joosten L, Oyen WJ et al (2012) Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer. Eur J Nucl Med Mol Imaging Res 2:1\u201311","journal-title":"Eur J Nucl Med Mol Imaging Res"},{"key":"1112_CR17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136\u2013151","journal-title":"Adv Drug Deliv Rev"},{"key":"1112_CR18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida S, Jones S, Bozic I et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114\u20131117","journal-title":"Nature"},{"key":"1112_CR19","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdu013","volume":"25","author":"A Kleger","year":"2014","unstructured":"Kleger A, Perkhofer L, Seufferlein T (2014) Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol 25:1260\u20131270","journal-title":"Ann Oncol"},{"key":"1112_CR20","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.3748\/wjg.v20.i31.10825","volume":"20","author":"SC Tang","year":"2014","unstructured":"Tang SC, Chen YC (2014) Novel therapeutic targets for pancreatic cancer. World J Gastroenterol 20:10825\u201310844","journal-title":"World J Gastroenterol"},{"key":"1112_CR21","first-page":"1819","volume":"13","author":"TM Gress","year":"1996","unstructured":"Gress TM, M\u00fcller-Pillasch F, Geng M et al (1996) A pancreatic cancer-specific expression profile. Oncogene 13:1819\u20131830","journal-title":"Oncogene"},{"key":"1112_CR22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/(SICI)1098-2264(199909)26:1<70::AID-GCC10>3.0.CO;2-A","volume":"26","author":"MM Geng","year":"1999","unstructured":"Geng MM, Ellenrieder V, Wallrapp C et al (1999) Use of representational difference analysis to study the effect of TGFB on the expression profile of a pancreatic cancer cell line. Gene Chromosomes Canc 26:70\u201379","journal-title":"Gene Chromosomes Canc"},{"key":"1112_CR23","first-page":"6265","volume":"63","author":"P Michl","year":"2003","unstructured":"Michl P, Barth C, Buchholz M et al (2003) Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 63:6265\u20136271","journal-title":"Cancer Res"},{"key":"1112_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000101049","volume":"74","author":"J Ueda","year":"2007","unstructured":"Ueda J, Semba S, Chiba H et al (2007) Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 74:32\u201341","journal-title":"Pathobiology"},{"key":"1112_CR25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1245\/s10434-010-1289-4","volume":"18","author":"CO Sung","year":"2011","unstructured":"Sung CO, Han SY, Kim SH (2011) Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol 18:273\u2013281","journal-title":"Ann Surg Oncol"},{"key":"1112_CR26","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.jss.2010.02.010","volume":"167","author":"H Jung","year":"2011","unstructured":"Jung H, Jun KH, Jung JH, Chin HM, Park WB (2011) The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. J Surg Res 167:e185\u2013e191","journal-title":"J Surg Res"},{"key":"1112_CR27","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-04-2770","volume":"65","author":"S Mima","year":"2005","unstructured":"Mima S, Tsutsumi S, Ushijima H et al (2005) Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res 65:1868\u20131876","journal-title":"Cancer Res"},{"key":"1112_CR28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10120-008-0497-0","volume":"12","author":"S Ohtani","year":"2009","unstructured":"Ohtani S, Terashima M, Satoh J et al (2009) Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival. Gastric Cancer 12:43\u201351","journal-title":"Gastric Cancer"},{"key":"1112_CR29","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1158\/0008-5472.CAN-05-1036","volume":"65","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, D'Souza T, Morin PJ (2005) Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 65:7378\u20137385","journal-title":"Cancer Res"},{"key":"1112_CR30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2015.08.019","volume":"369","author":"M Kuwada","year":"2015","unstructured":"Kuwada M, Chihara Y, Luo Y et al (2015) Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer. Cancer Lett 369:212\u2013221","journal-title":"Cancer Lett"},{"key":"1112_CR31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3892\/etm.2010.116","volume":"1","author":"TL Hwang","year":"2010","unstructured":"Hwang TL, Lee LY, Wang CC et al (2010) Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer. Exp Therap Med 1:789\u2013797","journal-title":"Exp Therap Med"},{"key":"1112_CR32","doi-asserted-by":"publisher","unstructured":"Jiwa LS, van Diest PJ, Hoefnagel LD et al (2014) Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer 14. doi: 10.1186\/1471-2407-14-864","DOI":"10.1186\/1471-2407-14-864"},{"key":"1112_CR33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6604486","volume":"99","author":"KA Landers","year":"2008","unstructured":"Landers KA, Samaratunga H, Teng L et al (2008) Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer 99:491\u2013501","journal-title":"Br J Cancer"},{"key":"1112_CR34","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4161\/cbt.8.19.9427","volume":"8","author":"J Li","year":"2009","unstructured":"Li J, Chigurupati S, Agarwal R et al (2009) Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol Ther 8:1806\u20131814","journal-title":"Cancer Biol Ther"},{"key":"1112_CR35","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/ijc.24159","volume":"124","author":"F Lanigan","year":"2009","unstructured":"Lanigan F, McKiernan E, Brennan DJ et al (2009) Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 124:2088\u20132097","journal-title":"Int J Cancer"},{"key":"1112_CR36","doi-asserted-by":"publisher","unstructured":"Liu JX, Wei ZY, Chen JS et al (2015) Prognostic and clinical significance of claudin-4 in gastric cancer: a meta-analysis. World J Surg Oncol 13. doi: 10.1186\/s12957-015-0626-2","DOI":"10.1186\/s12957-015-0626-2"},{"key":"1112_CR37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3892\/or.2015.4037","volume":"34","author":"X Ma","year":"2015","unstructured":"Ma X, Miao H, Jing B et al (2015) Claudin-4 controls the proliferation, apoptosis, migration and in vivo growth of MCF-7 breast cancer cells. Oncol Rep 34:681\u2013690","journal-title":"Oncol Rep"},{"key":"1112_CR38","doi-asserted-by":"crossref","first-page":"11087","DOI":"10.18632\/oncotarget.3571","volume":"6","author":"YF Cui","year":"2015","unstructured":"Cui YF, Liu AH, An DZ et al (2015) Claudin-4 is required for vasculogenic mimicry formation in human breast cancer cells. Oncotarget 6:11087\u201311097","journal-title":"Oncotarget"},{"key":"1112_CR39","doi-asserted-by":"publisher","unstructured":"Zhu JL, Gao P, Wang ZN et al (2013) Clinicopathological significance of claudin-4 in gastric carcinoma. World J Surg Oncol 11. doi: 10.1186\/1477-7819-11-150","DOI":"10.1186\/1477-7819-11-150"},{"key":"1112_CR40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00795-016-0135-6","volume":"49","author":"G Yamada","year":"2016","unstructured":"Yamada G, Murata M, Takasawa A et al (2016) Increased expressions of claudin 4 and 7 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Med Mol Morphol 49:163\u2013169","journal-title":"Med Mol Morphol"},{"key":"1112_CR41","first-page":"1185","volume":"22","author":"YL Choi","year":"2007","unstructured":"Choi YL, Kim J, Kwon MJ et al (2007) Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 22:1185\u20131195","journal-title":"Histol Histopathol"},{"key":"1112_CR42","first-page":"2567","volume":"9","author":"LBA Rangel","year":"2003","unstructured":"Rangel LBA, Agarwal R, D'Souza T et al (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567\u20132575","journal-title":"Clin Cancer Res"},{"key":"1112_CR43","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3892\/ol.2013.1198","volume":"5","author":"XY Pan","year":"2013","unstructured":"Pan XY, Li X, Che YC, Li HY, Zhang Y, Yang X (2013) Overexpression of claudin-4 may be involved in endometrial tumorigenesis. Oncol Lett 5:1422\u20131426","journal-title":"Oncol Lett"},{"key":"1112_CR44","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1002\/ijc.29632","volume":"137","author":"E Cocco","year":"2015","unstructured":"Cocco E, Shapiro EM, Gasparrini S et al (2015) Clostridium Perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer. Int J Cancer 137:2618\u20132629","journal-title":"Int J Cancer"},{"key":"1112_CR45","first-page":"131","volume":"6","author":"CA Foss","year":"2007","unstructured":"Foss CA, Fox JJ, Feldmann G et al (2007) Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging 6:131\u2013139","journal-title":"Mol Imaging"},{"key":"1112_CR46","first-page":"96","volume":"4","author":"JC Knight","year":"2014","unstructured":"Knight JC, Cornelissen B (2014) Bioorthogonal chemistry: implications for pretargeted nuclear (PET\/SPECT) imaging and therapy. Am J Nucl Med Mol Imaging 4:96\u2013113","journal-title":"Am J Nucl Med Mol Imaging"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-017-1112-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-017-1112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-017-1112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T08:53:13Z","timestamp":1602838393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-017-1112-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s11307-017-1112-8","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]}}}